Financings During the first quarter of 2016, biopharma financing totaled $5.7 billion, a 56% decrease over the previous quarter's $13.1 billion. (Keep in mind, over half of the Q4 2015 total came from
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc